AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship ...

Novo Nordisk slashed its spending on TV ads for Wegovy by almost 24% between April and May, from $31.6 million to $24.1 ...

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside. Read why ABBV stock is a hold.

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

The regulatory nod goes to risankizumab, a drug that North Chicago, Illinois-based AbbVie already sells under the name “Skyrizi” for approved uses in plaque psoriasis and psoriatic arthritis.

Offsetting Humira's expected declines, AbbVie looks well-positioned with next-generation immunology drugs. In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ...

The company is increasing its awareness campaign for cancer advocacy, including a partnership with the Chicago Cubs announced ...

Drug now approved for four conditions across different inflammatory diseases Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with ...

Advertisement Apart from the above indications, AbbVie is currently evaluating Skyrizi in a phase III study for ulcerative colitis. AbbVie is developing Skyrizi in collaboration with Boehringer ...

AbbVie ABBV announced that the FDA has approved its drug Skyrizi (risankizumab) for its third indication, moderately to severely active Crohn’s disease (“CD”). Skyrizi can now be used as a ...